Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track XERS with free AI briefings, catalyst countdowns, and dilution alerts.

XERS · Xeris Biopharma Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$121.7M Cash on Hand

CF+ Cash Runway

Follow XERS by email Get an email when XERS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about XERS, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Feb 2024 · Phase 2 · Results Expected · Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Registry primary completion date, not a results date
Apr 2020 · Phase 2 · Results Expected · Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formula
Registry primary completion date, not a results date
Apr 2020 · Phase 2 · Results Expected · Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic
Registry primary completion date, not a results date
Feb 2020 · Phase 2 · Results Expected · Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric
Registry primary completion date, not a results date
Mar 2019 · Phase 3 · Results Expected · G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Di
Registry primary completion date, not a results date
Sep 2018 · Phase 2 · Results Expected · CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Novo Glucagon	Insulin Hypoglycemia	Phase 3 · NCT03738865	Completed
Lilly Glucagon	Insulin Hypoglycemia	Phase 3 · NCT03439072	Completed
Pramlintide	Diabetes Mellitus, Type 1	Phase 2 · NCT04074317	Completed
Regular Insulin	Diabetes Mellitus, Type 1	Phase 2 · NCT04074317	Completed
PRAM9	Diabetes Mellitus, Type 1	Phase 2 · NCT04074317	Completed
Novo Nordisk GlucaGen®	Hypoglycemia	Phase 2 · NCT02081001	Completed
Glugaon RTU Injection Without Insulin Pu	Hypoglycemia	Phase 2 · NCT03841526	Completed
Glucagon RTU Injection With Insulin Pump	Hypoglycemia	Phase 2 · NCT03841526	Completed
G-Pen	Hypoglycemia	Phase 2 · NCT01972152	Completed
G-Pen Mini™ (glucagon injection)	Diabetes Mellitus, Type 1	Phase 2 · NCT02411578	Completed
XeriSol glucagon	Type1diabetes	Phase 1 · NCT03424044	Completed

Also used in these trials (approved or third-party drugs, not XERS's own candidates): Glucagon, Levothyroxine Sodium.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

XERS holds $121.7M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

No operating cash burn in latest filings
Share count +13% in a year +7

Recent financing filings on SEC EDGAR:

Jul 17, 2026 · Private placement (8-K Item 3.02) · 8-K
Jun 11, 2026 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XERS files for a raise →

Get the full XERS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XERS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z